Singapore markets open in 1 hour 12 minutes
Straits Times Index
3,255.54 +16.51 (+0.51%) S&P 500
3,971.27 -6.26 (-0.16%) Dow
32,394.25 -37.83 (-0.12%) Nasdaq
11,716.08 -52.76 (-0.45%) Bitcoin USD
27,297.41 +173.55 (+0.64%) CMC Crypto 200
598.52 +355.84 (+146.63%)
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 70.81 |
| Open | 70.81 |
| Bid | 69.29 x 800 |
| Ask | 71.33 x 800 |
| Day's range | 70.03 - 71.32 |
| 52-week range | 65.07 - 86.29 |
| Volume | |
| Avg. volume | 1,687,611 |
| Market cap | 15.677B |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 47.19 |
| EPS (TTM) | 1.49 |
| Earnings date | 01 May 2023 - 05 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 89.25 |
- Zacks
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
- Business Wire
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
WILMINGTON, Del. & TOKYO, March 27, 2023--Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
© 2023 Yahoo. All rights reserved.
